共 419 条
[1]
Aggarwal BB(2004)Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors Vitam Horm 67 453-483
[2]
Bhardwaj U(2007)Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry Cancer 109 1721-1728
[3]
Takada Y(2000)Validation of tissue microarray technology in breast carcinoma Lab Invest 80 1943-1949
[4]
Bauer KR(2013)A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer Ann Oncol 24 1777-1785
[5]
Brown M(1992)Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up Histopathology 20 479-489
[6]
Cress RD(1991)Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403-410
[7]
Parise CA(2002)Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 41 151-19
[8]
Caggiano V(2010)Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) Cancer Biother Radiopharm 25 13-219
[9]
Camp RL(1992)The Nottingham prognostic index in primary breast cancer Breast Cancer Res Treat 22 207-90
[10]
Charette LA(2008)Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer Lung Cancer 61 82-2840